Physician profile
Ahmad Yehya
NPI 1659780013
$8,186.94
in general payments reported to CMS, 2019-2025
35 companies · $1,674 in 2025
The $1,674 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $672 · 2021: $454 · 2022: $1,621 · 2023: $1,337 · 2024: $2,259 · 2025: $1,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,269.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,766.25 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $828.07 | 2020-2025 | Freestyle Libre, Freestyle Libre 3 |
| Novo Nordisk INC | $700.91 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.49 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $535.81 | 2019-2025 | Mounjaro, Jardiance, Baqsimi |
| Amgen INC. | $501.78 | 2019-2025 | Tepezza, Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $489.94 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $318.80 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $253.94 | 2019-2025 | Ubrelvy, Synthroid |
| Bayer Healthcare Pharmaceuticals INC. | $246.44 | 2022-2025 | |
| Corcept Therapeutics | $241.18 | 2020-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $201.65 | 2019-2023 | Farxiga |
| Cequr Corporation | $195.44 | 2024-2025 | Cequr Simplicity |
| Radius Health, INC. | $184.37 | 2020-2025 | Tymlos |
| Medtronic, INC. | $136.89 | 2021-2025 | Minimed 780g |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $119.31 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $112.65 | 2019-2022 | |
| Pfizer INC. | $112.32 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $104.01 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $65.31 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $61.09 | 2024-2025 | Omnipod |
| Recordati_rare_diseases_inc. | $54.14 | 2025 | Isturisa |
| Avvisto Therapeutics, LLC | $48.74 | 2025 | Cycloset |
| Ibsa Pharma INC. | $48.49 | 2022-2023 | Tirosint, Licart |
| Beta Bionics, INC. | $42.75 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amneal Pharmaceuticals LLC | $42.06 | 2020-2025 | Unithroid |
| Amarin Pharma, INC. | $41.62 | 2019-2020 | |
| Medtronic Minimed, INC. | $35.21 | 2020 | |
| Alexion Pharmaceuticals, INC. | $33.30 | 2025 | Strensiq |
| Grt US Holding, INC. | $28.83 | 2021-2022 | |
| Esperion Therapeutics, INC. | $23.46 | 2024 | Nexletol |
| Kyowa Kirin, INC. | $19.07 | 2024 | Crysvita |
| Becton, Dickinson and Company | $18.21 | 2020 | |
| Horizon Therapeutics Plc | $17.08 | 2023 | Tepezza |
| Almatica Pharma LLC | $15.33 | 2025 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Yehya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.